Journal: Scientific Reports

Article Title: EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients

doi: 10.1038/s41598-019-43678-6

Figure Lengend Snippet: Protein expression and frequency distribution in primary and metastatic lung cancer tissue. EGFR protein immunohistochemistry ( A ) and HER3 protein immunohistochemistry ( B ) was performed on tissue microarray from primary NSCLC tumors and brain metastases. Representative strong (left), intermediate (center) and negative (right) staining are shown in 200x magnification (Zeiss Axiovision).

Article Snippet: For HER3 we tested two different antibodies; the biotinylated human anti-HER3 antibody (clone REA508; Miltenyi Biotec, Bergisch Gladbach, Germany) and the biotinylated human anti-HER-3 antibody (clone 1B4C3; BioLegend, San Diego, California).

Techniques: Expressing, Immunohistochemistry, Microarray, Staining

Journal: Scientific Reports

Article Title: EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients

doi: 10.1038/s41598-019-43678-6

Figure Lengend Snippet: EGFR ( A ) and HER3 ( B ) expression distribution in primary lung, lymph node and brain metastatic tissue and association between HER3 protein expression in primary and clinicopathological parameters ( C ). HER3 is more frequently expressed in brain metastasis of oligo-brain metastatic patients (p = 0.028) compared to patients with other metastatic sites. HER3 expression in primary NSCLC tumors is significantly associated with a decreased time to metastatic progression (p = 0.006; log-rank test) ( D ) and decreased relapse-free survival time (p = 0.013; log-rank test) ( E ).

Article Snippet: For HER3 we tested two different antibodies; the biotinylated human anti-HER3 antibody (clone REA508; Miltenyi Biotec, Bergisch Gladbach, Germany) and the biotinylated human anti-HER-3 antibody (clone 1B4C3; BioLegend, San Diego, California).

Techniques: Expressing

Journal: Scientific Reports

Article Title: EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients

doi: 10.1038/s41598-019-43678-6

Figure Lengend Snippet: CTC positivity rates in NSCLC patients (n = 45). ( A ) Significantly higher detection rates when combining the methods in comparison to either single use CellSearch (p = 0.0023) or magnetic cell separation with EGFR/HER3 (p = 0.0109). ( B ) CTC enumeration detected by CellSearch and MACS.

Article Snippet: For HER3 we tested two different antibodies; the biotinylated human anti-HER3 antibody (clone REA508; Miltenyi Biotec, Bergisch Gladbach, Germany) and the biotinylated human anti-HER-3 antibody (clone 1B4C3; BioLegend, San Diego, California).

Techniques: Comparison, Magnetic Cell Separation

Journal: Scientific Reports

Article Title: EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients

doi: 10.1038/s41598-019-43678-6

Figure Lengend Snippet: Representative images of two Circulating Tumor Cell cluster (DAPI + /CD45 − /CK + ) isolated via magnetic cell separation with HER3-protein antibody in one NSCLC patient. Heterogeneous MET expression was found within the cluster as well as CD45-positive leukocytes.

Article Snippet: For HER3 we tested two different antibodies; the biotinylated human anti-HER3 antibody (clone REA508; Miltenyi Biotec, Bergisch Gladbach, Germany) and the biotinylated human anti-HER-3 antibody (clone 1B4C3; BioLegend, San Diego, California).

Techniques: Isolation, Magnetic Cell Separation, Expressing